Passion & Purpose in Women’s Oncology
Founded in late 2014 by David Portman, MD, a leading clinical researcher and expert in women’s health, menopause, and selective estrogen receptor modulators, Sermonix Pharmaceuticals is a privately held biotechnology company focused on the development and commercialization of female-specific oncology products.
The ELAINE Study
The ELAINE Study is an open-label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor 2-negative (HER2-) breast cancer with an acquired estrogen receptor 1 (ESR1) mutation and who have disease progression on an aromatase inhibitor (Al) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor.*
The primary objective is to evaluate the progression-free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of postmenopausal women and premenopausal women on ovarian suppression with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation.
*AIs include Arimidex (anastrozole), Femara (letrozole), or Aromasin (exemestane). CDK 4/6 inhibitors include Kisqali (ribociclib), Ibrance (palbociclib), and Verzenio (abemaciclib).
All product names, trademarks, and registered trademarks are property of their respective owners.
We are investigating whether lasofoxifene may benefit certain women with metastatic breast cancer by delaying disease progression while offering a differentiated safety profile. See if you prequalify for The ELAINE Study.
Use the ZIP Code locator to find contact information for the study location nearest you.